Sergey Burd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergey Burd has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Yulia V. Rubleva
Federal Center of Brain Research and Neurotechnologies
18 shared publications - Mikhail Borisovich Mironov
Federal Center of Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
14 shared publications - N. V. Pantina
Federal Center of Brain Research and Neurotechnologies
13 shared publications - Anna V. Lebedeva
Federal Center for Brain and Neurotechnologies of the Federal Medical Biological Agency of Russia
12 shared publications - I. I. Kovaleva
Federal Center for Brain and Neurotechnologies
11 shared publications - A. V. Yurchenko
Federal Center of Brain Research and Neurotechnologies
7 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 80-96
Epilepsy in patients with Down syndrome (literature review and clinical cases)
An overview of the literature and clinical cases of epilepsy in Down syndrome (DS) is presented. Epilepsy in DS has a bimodal distribution with two peaks: before 5 years of age and after 40 years. In childhood, the most common epileptic syndrome is infantile epileptic spasms syndrome. First-line treatment includes vigabatrin and corticosteroids. The second peak of epilepsy occurs after the age of 40 and is associated with the coexistence of epilepsy and Alzheimer’s disease, which is known as late-onset myoclonic epilepsy in DS, the seizure semiology of which is similar to that of juvenile myoclonic epilepsy. Clinical cases of patients with infantile epileptic spasms syndrome and DS successfully treated with vigabatrin are presented. Comorbidities in DS include a high prevalence of obstructive sleep apnea syndrome, increased carbonic anhydrase type 2 activity, and the presence of myoclonic seizures similar to those in juvenile myoclonic epilepsy. These features support the use of sultiame as a pathogenetically justified drug for the treatment of epilepsy in patients with AD. A clinical case of a patient with DS is presented, in whom sultiame demonstrated high efficacy and good tolerability, as well as a positive impact on development and behavior
- 30 July 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (2) , 80-96
Open AccessEpilepsy in patients with Down syndrome (literature review and clinical cases)
An overview of the literature and clinical cases of epilepsy in Down syndrome (DS) is presented. Epilepsy in DS has a bimodal distribution with two peaks: before 5 years of age and after 40 years. In childhood, the most common epileptic syndrome is infantile epileptic spasms syndrome. First-line treatment includes vigabatrin and corticosteroids. The second peak of epilepsy occurs after the age of 40 and is associated with the coexistence of epilepsy and Alzheimer’s disease, which is known as late-onset myoclonic epilepsy in DS, the seizure semiology of which is similar to that of juvenile myoclonic epilepsy. Clinical cases of patients with infantile epileptic spasms syndrome and DS successfully treated with vigabatrin are presented. Comorbidities in DS include a high prevalence of obstructive sleep apnea syndrome, increased carbonic anhydrase type 2 activity, and the presence of myoclonic seizures similar to those in juvenile myoclonic epilepsy. These features support the use of sultiame as a pathogenetically justified drug for the treatment of epilepsy in patients with AD. A clinical case of a patient with DS is presented, in whom sultiame demonstrated high efficacy and good tolerability, as well as a positive impact on development and behavior
- 29 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 63-69
Myoclonus in Alzheimer’s disease
Neurodegenerative diseases are often presented with myoclonus, sudden, short-term, involuntary muscle contractions («flinching»). According to the literature, myoclonus in Alzheimer’s disease (AD) can occur up to 40—50% in cases of disease with early onset and in atypical forms. Importantly, epileptic myoclonus may indicate a risk of seizures with loss of consciousness, convulsions, and epileptiform activity, which may lead to more rapid progression of cognitive deficits. Diagnosis of myoclonus is essential for timely treatment and improving the quality of life of AD patients. The paper describes the main features of myoclonus in AD, the possibility of using additional examination methods, in particular video-electroencephalographic (video-EEG) monitoring for differential diagnosis and etiology clarification, and also presents a clinical case of a patient with AD and epileptic and non-epileptic myoclonus.
- 29 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 63-69
Myoclonus in Alzheimer’s disease
Neurodegenerative diseases are often presented with myoclonus, sudden, short-term, involuntary muscle contractions («flinching»). According to the literature, myoclonus in Alzheimer’s disease (AD) can occur up to 40—50% in cases of disease with early onset and in atypical forms. Importantly, epileptic myoclonus may indicate a risk of seizures with loss of consciousness, convulsions, and epileptiform activity, which may lead to more rapid progression of cognitive deficits. Diagnosis of myoclonus is essential for timely treatment and improving the quality of life of AD patients. The paper describes the main features of myoclonus in AD, the possibility of using additional examination methods, in particular video-electroencephalographic (video-EEG) monitoring for differential diagnosis and etiology clarification, and also presents a clinical case of a patient with AD and epileptic and non-epileptic myoclonus.
- 15 January 2026
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 27 (4)
Treatment of drug-resistant epilepsy associated with temporal lobe cavernomas
Pharmacoresistance (drug-resistance) occurs in 40 % of cases of structural epilepsy associated with cavernous malformations. The surgical strategy in the treatment of such patients aims, on one hand, to eliminate the epileptogenic focus and achieve seizure control; on the other hand, to remove the cavernoma and eliminate the risk of recurrent hemorrhage. The following surgical options are identified: 1) removal of only the cavernous malformation; 2) microsurgical removal of the cavernoma with a perifocal area of hemosiderin and a zone of gliosis; 3) stereotactic radiosurgery method. In cases of temporal cavernoma, anterior medial temporal lobectomy is highlighted as an additional method of surgical treatment. This localization requires a special approach to the choice of surgical strategy depending on the location of the cavernoma in relation to the structures of the hippocampal complex, the presence of secondary epileptogenic foci and the duration of epilepsy. Aim of the work – to analyze the current data on the examined topic, aspects of surgical treatment of patients with structural focal epilepsy associated with cavernomas, using the example of three clinical cases. Clinical examples are presented based on data from three patients operated on at the Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency (FMBA) of Russia between 2022 and 2023. A literature review was conducted on treatment options for this category of patients. Articles were searched on the scientific platforms PubMed, Cochrane Library, eLIBRARY. RU, and the Journal of Neurosurgery, using the following search terms: cavernous malformation, structural epilepsy, temporal focal epilepsy.
- 15 January 2026
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 27 (4)
Treatment of drug-resistant epilepsy associated with temporal lobe cavernomas
Pharmacoresistance (drug-resistance) occurs in 40 % of cases of structural epilepsy associated with cavernous malformations. The surgical strategy in the treatment of such patients aims, on one hand, to eliminate the epileptogenic focus and achieve seizure control; on the other hand, to remove the cavernoma and eliminate the risk of recurrent hemorrhage. The following surgical options are identified: 1) removal of only the cavernous malformation; 2) microsurgical removal of the cavernoma with a perifocal area of hemosiderin and a zone of gliosis; 3) stereotactic radiosurgery method. In cases of temporal cavernoma, anterior medial temporal lobectomy is highlighted as an additional method of surgical treatment. This localization requires a special approach to the choice of surgical strategy depending on the location of the cavernoma in relation to the structures of the hippocampal complex, the presence of secondary epileptogenic foci and the duration of epilepsy. Aim of the work – to analyze the current data on the examined topic, aspects of surgical treatment of patients with structural focal epilepsy associated with cavernomas, using the example of three clinical cases. Clinical examples are presented based on data from three patients operated on at the Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency (FMBA) of Russia between 2022 and 2023. A literature review was conducted on treatment options for this category of patients. Articles were searched on the scientific platforms PubMed, Cochrane Library, eLIBRARY. RU, and the Journal of Neurosurgery, using the following search terms: cavernous malformation, structural epilepsy, temporal focal epilepsy.
- 9 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 36-43
Epileptic seizures in patients with Alzheimer’s disease
Neurodegenerative diseases are one of the leading causes of epileptic seizures with onset in later life. Particular attention is paid to Alzheimer’s disease (AD), as a disease that accounts for up to 70% of cases of all types of dementia, and, according to the literature, shares genetic and pathophysiological mechanisms with epilepsy. This paper reviews the literature on the prevalence of epilepsy in AD patients. The reasons for the widely varying data (ranging from 0.5 to 64%) depending on the selected population, the reliability of the established diagnosis, the form and genetic characteristics of the disease, as well as the examination methods used, are considered. The main risk factors for the development of AD and epilepsy, semiotics and features of seizures in patients with AD, as well as approaches to the treatment of such patients, are also covered.
- 9 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 36-43
Epileptic seizures in patients with Alzheimer’s disease
Neurodegenerative diseases are one of the leading causes of epileptic seizures with onset in later life. Particular attention is paid to Alzheimer’s disease (AD), as a disease that accounts for up to 70% of cases of all types of dementia, and, according to the literature, shares genetic and pathophysiological mechanisms with epilepsy. This paper reviews the literature on the prevalence of epilepsy in AD patients. The reasons for the widely varying data (ranging from 0.5 to 64%) depending on the selected population, the reliability of the established diagnosis, the form and genetic characteristics of the disease, as well as the examination methods used, are considered. The main risk factors for the development of AD and epilepsy, semiotics and features of seizures in patients with AD, as well as approaches to the treatment of such patients, are also covered.
- Open Access
- 17 November 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (4) , 578-586
Diagnostic significance of subclinical epileptiform activity in patients with alzheimer’s disease
Introduction. The high prevalence and significant disability of patients with Alzheimer’s disease (AD) necessitate the search for new markers of disease progression and novel treatment approaches. Recent evidence is increasingly attracting the research attention to the value of electroencephalography (EEG) in detecting epileptiform activity in this patient population. Objective . Detection of the frequency of epileptiform activity in patients with AD and evaluation of its clinical and diagnostic significance. Discussion . EEG, in particular, prolonged sleep-deprived EEG, is capable of detecting subclinical epileptiform activity, which is associated with more severe cognitive impairments and contributes to disease progression. This review examines research data on the prevalence and clinical significance of subclinical epileptiform activity in AD patients without an epilepsy diagnosis. It also highlights key pathophysiological mechanisms linking epileptiform activity to the progression of cognitive decline in AD. Furthermore, it addresses the rationale for prescribing specific antiepileptic therapy upon detection of subclinical epileptiform activity. Conclusions. The high clinical significance of performing electroencephalography and detecting epileptiform activity in patients with Alzheimer’s disease, due to its potential negative impact on the progression of cognitive impairments and increased risks of developing epileptic seizures, has been demonstrated.
- 17 November 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (4) , 578-586
Open AccessDiagnostic significance of subclinical epileptiform activity in patients with alzheimer’s disease
Introduction. The high prevalence and significant disability of patients with Alzheimer’s disease (AD) necessitate the search for new markers of disease progression and novel treatment approaches. Recent evidence is increasingly attracting the research attention to the value of electroencephalography (EEG) in detecting epileptiform activity in this patient population. Objective . Detection of the frequency of epileptiform activity in patients with AD and evaluation of its clinical and diagnostic significance. Discussion . EEG, in particular, prolonged sleep-deprived EEG, is capable of detecting subclinical epileptiform activity, which is associated with more severe cognitive impairments and contributes to disease progression. This review examines research data on the prevalence and clinical significance of subclinical epileptiform activity in AD patients without an epilepsy diagnosis. It also highlights key pathophysiological mechanisms linking epileptiform activity to the progression of cognitive decline in AD. Furthermore, it addresses the rationale for prescribing specific antiepileptic therapy upon detection of subclinical epileptiform activity. Conclusions. The high clinical significance of performing electroencephalography and detecting epileptiform activity in patients with Alzheimer’s disease, due to its potential negative impact on the progression of cognitive impairments and increased risks of developing epileptic seizures, has been demonstrated.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 103-116
Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)
Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 103-116
Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)
Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
- Open Access
- 15 April 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1533767
A Phase 4, multicenter, prospective, non-interventional, observational study to investigate the effectiveness and safety/tolerability of perampanel when used as first adjunctive therapy in routine clinical practice in people with epilepsy: Study 512
Introduction: Study 512 aimed to assess the efficacy and safety of perampanel (PER) as the first add-on therapy.Methods: In this 12-month, prospective, observational, multicenter study, people with epilepsy (PWE) aged ≥12 years with focal-onset seizures or generalized tonic–clonic seizures (GTCS) associated with idiopathic generalized epilepsy received PER as the first add-on therapy to antiseizure medication (ASM) monotherapy. The primary efficacy endpoint was the retention rate at 12 months. Other endpoints included change in seizure frequency from baseline; pragmatic seizure freedom rate (proportion of PWE in the full analysis set achieving freedom from all seizures); responder rate (≥50% seizure frequency reduction from baseline), changes from baseline in the 10-item Quality of Life in Epilepsy questionnaire (QOLIE-10) total score, the Epworth Sleepiness Scale (ESS), and the age-corrected EpiTrack and EpiTrack Junior total score; safety/tolerability (treatment-emergent adverse events [TEAEs]); and PER dose.Results: Of 184 PWE (Safety Set, n = 182; Full Analysis Set, n = 174), 135 (73.4%) completed the 12-month study. The mean PER dose was 4.7 mg/day. Retention rate at 12 months was 74.2% in the overall population, 81.8% in the 12 to <18 years age group, 74.3% in the 18 to <65 years age group, and 66.7% in the ≥65 years age group. Retention rates were similar between PWE with focal-onset seizures (74.5%) and GTCS (75.0%). The median reduction in monthly seizure frequency per 28 days from baseline to 12 months was 78.6% in the overall population, 92.3% in the 12 to <18 age group, 75.0% in the 18 to <65 years age group, and 87.5% in the ≥65 years age group. In the overall population, pragmatic seizure freedom rates at 12 months were 36.2% (all seizures), 34.1% (all focal seizures), and 45.5% (GTCS); the responder rate at 12 months was 64.4% in the overall population. In total, 52.7% of PWE experienced TEAEs, and 12.1% discontinued due to TEAEs. No significant changes were identified from baseline to 12 months in QOLIE-10, ESS, and the age-corrected EpiTrack and EpiTrack Junior scores.Conclusion: PER was efficacious for focal and generalized seizures across all age groups and was generally well-tolerated, as demonstrated by the high retention rates at 12 months.
- 15 April 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1533767
Open AccessA Phase 4, multicenter, prospective, non-interventional, observational study to investigate the effectiveness and safety/tolerability of perampanel when used as first adjunctive therapy in routine clinical practice in people with epilepsy: Study 512
Introduction: Study 512 aimed to assess the efficacy and safety of perampanel (PER) as the first add-on therapy.Methods: In this 12-month, prospective, observational, multicenter study, people with epilepsy (PWE) aged ≥12 years with focal-onset seizures or generalized tonic–clonic seizures (GTCS) associated with idiopathic generalized epilepsy received PER as the first add-on therapy to antiseizure medication (ASM) monotherapy. The primary efficacy endpoint was the retention rate at 12 months. Other endpoints included change in seizure frequency from baseline; pragmatic seizure freedom rate (proportion of PWE in the full analysis set achieving freedom from all seizures); responder rate (≥50% seizure frequency reduction from baseline), changes from baseline in the 10-item Quality of Life in Epilepsy questionnaire (QOLIE-10) total score, the Epworth Sleepiness Scale (ESS), and the age-corrected EpiTrack and EpiTrack Junior total score; safety/tolerability (treatment-emergent adverse events [TEAEs]); and PER dose.Results: Of 184 PWE (Safety Set, n = 182; Full Analysis Set, n = 174), 135 (73.4%) completed the 12-month study. The mean PER dose was 4.7 mg/day. Retention rate at 12 months was 74.2% in the overall population, 81.8% in the 12 to <18 years age group, 74.3% in the 18 to <65 years age group, and 66.7% in the ≥65 years age group. Retention rates were similar between PWE with focal-onset seizures (74.5%) and GTCS (75.0%). The median reduction in monthly seizure frequency per 28 days from baseline to 12 months was 78.6% in the overall population, 92.3% in the 12 to <18 age group, 75.0% in the 18 to <65 years age group, and 87.5% in the ≥65 years age group. In the overall population, pragmatic seizure freedom rates at 12 months were 36.2% (all seizures), 34.1% (all focal seizures), and 45.5% (GTCS); the responder rate at 12 months was 64.4% in the overall population. In total, 52.7% of PWE experienced TEAEs, and 12.1% discontinued due to TEAEs. No significant changes were identified from baseline to 12 months in QOLIE-10, ESS, and the age-corrected EpiTrack and EpiTrack Junior scores.Conclusion: PER was efficacious for focal and generalized seizures across all age groups and was generally well-tolerated, as demonstrated by the high retention rates at 12 months.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (12) , 14-19
Ototoxicity caused by anti-epileptic drugs
According to the literature, a number of anti-epileptic drugs (AEDs) have an ototoxic effect. The mechanism of hearing dysfunction due to the use of AEDs is not well known. The main clinical manifestations of the cochleotoxic effect of the drugs are: tinnitus, sensorineural hearing loss, impaired pitch perception, hyperacusis. These disorders can be reversible and irreversible. Attending physicians should be careful when prescribing AEDs to patients who have had hearing impairment before, as well as diagnose hearing loss in a timely manner with subsequent correction of anti-epileptic therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (12) , 14-19
Ototoxicity caused by anti-epileptic drugs
According to the literature, a number of anti-epileptic drugs (AEDs) have an ototoxic effect. The mechanism of hearing dysfunction due to the use of AEDs is not well known. The main clinical manifestations of the cochleotoxic effect of the drugs are: tinnitus, sensorineural hearing loss, impaired pitch perception, hyperacusis. These disorders can be reversible and irreversible. Attending physicians should be careful when prescribing AEDs to patients who have had hearing impairment before, as well as diagnose hearing loss in a timely manner with subsequent correction of anti-epileptic therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 158-164
The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study)
Objective. To study the efficacy and safety of the use of high (200 mg) doses of uridine monophosphate in combination with choline (dietary supplement, dietary supplement, Neururidine N) in the treatment of patients with nonspecific back pain. Material and methods. An open observational study was conducted, which included 101 patients with acute PB; group 1 included 65 patients who received Neurouridine N (1 caps/day) meloxicam (7.5—15 mg/day) and meloxicam (7.5—15 mg/day), 2nd — 36 patients who received only meloxicam (7.5—15 mg/day). The observation period is 30 days. The condition of the patients was assessed on the basis of a visual analog scale (VAS), Roland—Morris questionnaires (ORM) and general clinical impression (CGI). Results. The positive effect of treatment on reducing the severity of pain was noted according to the results of the VAS assessment. In patients of group 1, an earlier improvement in functional status was noted (starting from day 7) according to ORM data (p<0.01), A more pronounced decrease in pain intensity allowed patients of group 1 to stop taking NSAIDs after 14 days (p<0.01). Patients of the 1st group were statistically significantly more satisfied with the results of treatment (CGI questionnaire), the doctors who observed them also regarded the improvement in their condition as more significant compared to the 2nd group. Conclusion. The use of dietary supplement Neururidine N is an effective and safe method of coanalgesic therapy in patients with acute LBP.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 158-164
The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study)
Objective. To study the efficacy and safety of the use of high (200 mg) doses of uridine monophosphate in combination with choline (dietary supplement, dietary supplement, Neururidine N) in the treatment of patients with nonspecific back pain. Material and methods. An open observational study was conducted, which included 101 patients with acute PB; group 1 included 65 patients who received Neurouridine N (1 caps/day) meloxicam (7.5—15 mg/day) and meloxicam (7.5—15 mg/day), 2nd — 36 patients who received only meloxicam (7.5—15 mg/day). The observation period is 30 days. The condition of the patients was assessed on the basis of a visual analog scale (VAS), Roland—Morris questionnaires (ORM) and general clinical impression (CGI). Results. The positive effect of treatment on reducing the severity of pain was noted according to the results of the VAS assessment. In patients of group 1, an earlier improvement in functional status was noted (starting from day 7) according to ORM data (p<0.01), A more pronounced decrease in pain intensity allowed patients of group 1 to stop taking NSAIDs after 14 days (p<0.01). Patients of the 1st group were statistically significantly more satisfied with the results of treatment (CGI questionnaire), the doctors who observed them also regarded the improvement in their condition as more significant compared to the 2nd group. Conclusion. The use of dietary supplement Neururidine N is an effective and safe method of coanalgesic therapy in patients with acute LBP.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 171-177
Brain microstructural abnormalities assessed by diffusion kurtosis MRI in patients with focal temporal lobe epilepsy
Objective. To study microstructural abnormalities in epileptogenic focus and in mirror region by diffusion kurtosis (DK) MRI in patients with focal temporal lobe epilepsy. Material and methods. The main group included 12 patients (mean age 35 [30.5; 39.0] years, 5 women) with a diagnosis of focal epilepsy in the right temporal lobe (r-TL). The control group consisted of 15 healthy volunteers (mean age 33 [29.0; 39.0] years, 5 women). In both groups all participants underwent clinical and neurologic assessments, EEG and video EEG monitoring, and MRI, including DK MRI. Evaluation of microstructural changes in the temporal lobes included the study of 10 DK parameters. Results. In the main group, focal motor/nonmotor or bilateral tonic-clonic seizures were observed in 9 and 11 patients. Ten (83%) patients had focal epileptic activity on routine EEG in the r-TL and 9 (75%) patients had MRI focal changes in the same lobe. There was a significant decrease in fractional (FA) and kurtosis anisotropy (KA), mean (MK), radial (RK), and axial kurtosis (AK), as well as in axonal water fraction (AWF) in the r-TL of patients with epilepsy compared to the control group. Besides, FA, KA, MK, RK, AK, and AWF parameters in the l-TL in the main group were significantly reduced compared to the l-TL in the controls. There was a significant association between the duration of epilepsy, axial and radial extra axonal diffusion as well as axonal diffusivity in the l-TL. No association was observed in the r-TL. In the control group, MK, AK, RK, and AWF positively correlated with age. No correlation between age and MK, AK, RK, and AWF was found in the main group. Conclusion. In patients with an epileptic focus in the r-TL, microstructural changes are observed not only in the area of the epileptic focus, but also in the affected temporal lobe as a whole, and also mirrored in the conditionally healthy temporal lobe. Altered microstructure in the mirror region may reflect changes secondary to bilateral tonic-clonic seizures or evolution to secondary epileptogenic zone. Assessment of DK MRI parameters may provide additional information about the epileptogenic focus and the extent of microstructural abnormalities.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 171-177
Brain microstructural abnormalities assessed by diffusion kurtosis MRI in patients with focal temporal lobe epilepsy
Objective. To study microstructural abnormalities in epileptogenic focus and in mirror region by diffusion kurtosis (DK) MRI in patients with focal temporal lobe epilepsy. Material and methods. The main group included 12 patients (mean age 35 [30.5; 39.0] years, 5 women) with a diagnosis of focal epilepsy in the right temporal lobe (r-TL). The control group consisted of 15 healthy volunteers (mean age 33 [29.0; 39.0] years, 5 women). In both groups all participants underwent clinical and neurologic assessments, EEG and video EEG monitoring, and MRI, including DK MRI. Evaluation of microstructural changes in the temporal lobes included the study of 10 DK parameters. Results. In the main group, focal motor/nonmotor or bilateral tonic-clonic seizures were observed in 9 and 11 patients. Ten (83%) patients had focal epileptic activity on routine EEG in the r-TL and 9 (75%) patients had MRI focal changes in the same lobe. There was a significant decrease in fractional (FA) and kurtosis anisotropy (KA), mean (MK), radial (RK), and axial kurtosis (AK), as well as in axonal water fraction (AWF) in the r-TL of patients with epilepsy compared to the control group. Besides, FA, KA, MK, RK, AK, and AWF parameters in the l-TL in the main group were significantly reduced compared to the l-TL in the controls. There was a significant association between the duration of epilepsy, axial and radial extra axonal diffusion as well as axonal diffusivity in the l-TL. No association was observed in the r-TL. In the control group, MK, AK, RK, and AWF positively correlated with age. No correlation between age and MK, AK, RK, and AWF was found in the main group. Conclusion. In patients with an epileptic focus in the r-TL, microstructural changes are observed not only in the area of the epileptic focus, but also in the affected temporal lobe as a whole, and also mirrored in the conditionally healthy temporal lobe. Altered microstructure in the mirror region may reflect changes secondary to bilateral tonic-clonic seizures or evolution to secondary epileptogenic zone. Assessment of DK MRI parameters may provide additional information about the epileptogenic focus and the extent of microstructural abnormalities.